Cancer

Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment, and adoptive transfer of CD8⁺ tumor-infiltrating lymphocytes (TILs) pretreated with the inhibitor decreased tumor growth. In a mouse model of metastatic melanoma, T cell-specific knockout of GSK3 decreased lung metastasis compared with normal expression, and the GSK inhibitor decreased primary tumor growth and lung metastasis and increased survival compared with no treatment. Next steps could include testing GSK3 inhibitors in additional lymphoma and melanoma models...